In the observed cohorts we observed a significantly longer OS of I-IPMN, however no differences in pathological, CA19.9, PET, and radiological response to NAT between I-IPMN and PDAC was observed. This evidence concerns the gene BRD2 and pancreatic intraductal papillary-mucinous neoplasm.